Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor

Anand Divakaran; Siva K. Talluri; Alex M. Ayoub; Neeraj K. Mishra; Huarui Cui; John C. Widen; Norbert Berndt; Jin Yi Zhu; Angela S. Carlson; Joseph J. Topczewski; Ernst K. Schonbrunn; Daniel A. Harki; William C.K. Pomerantz

doi:10.1021/acs.jmedchem.8b01248

Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor

Anand Divakaran, Siva K. Talluri, Alex M. Ayoub, Neeraj K. Mishra, Huarui Cui, John C. Widen, Norbert Berndt, Jin Yi Zhu, Angela S. Carlson, Joseph J. Topczewski, Ernst K. Schonbrunn, Daniel A. Harki, William C.K. Pomerantz

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

As regulators of transcription, epigenetic proteins that interpret post-translational modifications to N-terminal histone tails are essential for maintaining cellular homeostasis. When dysregulated, "reader" proteins become drivers of disease. In the case of bromodomains, which recognize N-ϵ-acetylated lysine, selective inhibition of individual bromodomain-and-extra-terminal (BET)-family bromodomains has proven challenging. We describe the >55-fold N-terminal-BET bromodomain selectivity of 1,4,5-trisubstituted-imidazole dual kinase-bromodomain inhibitors. Selectivity for the BRD4 N-terminal bromodomain (BRD4(1)) over its second bromodomain (BRD4(2)) arises from the displacement of ordered waters and the conformational flexibility of lysine-141 in BRD4(1). Cellular efficacy was demonstrated via reduction of c-Myc expression, inhibition of NF-κB signaling, and suppression of IL-8 production through potential synergistic inhibition of BRD4(1) and p38α. These dual inhibitors provide a new scaffold for domain-selective inhibition of BRD4, the aberrant function of which plays a key role in cancer and inflammatory signaling.

Original language	English (US)
Pages (from-to)	9316-9334
Number of pages	19
Journal	Journal of medicinal chemistry
Volume	61
Issue number	20
DOIs	https://doi.org/10.1021/acs.jmedchem.8b01248
State	Published - Oct 25 2018

Bibliographical note

Funding Information:
This work was supported by the NSF (Grant CHE-1352019, W.C.K.P.) AHA (Grant 15SDG25710427, W.C.K.P.), NIGMS (Grant R35GM124718), and the University of Minnesota Masonic Cancer Center (Pre-R01 pilot grant D.A.H. and W.C.K.P.). A.D. was supported by the NIH Chemistry-Biology Interface Training Grant at the University of Minnesota (5T32GM008700-18). Isothermal-titration calorimetry and nuclear-magnetic-resonance spectroscopy were carried out using instruments funded by NIH Shared Instrumentation Grants (S10-OD017982 and S10-OD011952, respectively). We also thank the Moffitt Chemical Biology Core for use of the protein crystallography facility (NCI Grant P30-CA076292). BI-BODIPY was a generous gift from Wei Zhang at the University of Massachusetts, Boston. We thank Prof. Brian Smith for providing the BRD4 Bromodomain construct BRD4 (1 + 2) spanning residues 38-460.

Access

10.1021/acs.jmedchem.8b01248

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245549

Fingerprint Dive into the research topics of 'Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor'. Together they form a unique fingerprint.

Cite this

Divakaran, A., Talluri, S. K., Ayoub, A. M., Mishra, N. K., Cui, H., Widen, J. C., Berndt, N., Zhu, J. Y., Carlson, A. S., Topczewski, J. J., Schonbrunn, E. K., Harki, D. A., & Pomerantz, W. C. K. (2018). Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. Journal of medicinal chemistry, 61(20), 9316-9334. https://doi.org/10.1021/acs.jmedchem.8b01248

Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. / Divakaran, Anand; Talluri, Siva K.; Ayoub, Alex M.; Mishra, Neeraj K.; Cui, Huarui; Widen, John C.; Berndt, Norbert; Zhu, Jin Yi; Carlson, Angela S.; Topczewski, Joseph J.; Schonbrunn, Ernst K.; Harki, Daniel A.; Pomerantz, William C.K.

In: Journal of medicinal chemistry, Vol. 61, No. 20, 25.10.2018, p. 9316-9334.

Research output: Contribution to journal › Article › peer-review

Divakaran, A, Talluri, SK, Ayoub, AM, Mishra, NK, Cui, H, Widen, JC, Berndt, N, Zhu, JY, Carlson, AS, Topczewski, JJ, Schonbrunn, EK, Harki, DA & Pomerantz, WCK 2018, 'Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor', Journal of medicinal chemistry, vol. 61, no. 20, pp. 9316-9334. https://doi.org/10.1021/acs.jmedchem.8b01248

Divakaran, Anand ; Talluri, Siva K. ; Ayoub, Alex M. ; Mishra, Neeraj K. ; Cui, Huarui ; Widen, John C. ; Berndt, Norbert ; Zhu, Jin Yi ; Carlson, Angela S. ; Topczewski, Joseph J. ; Schonbrunn, Ernst K. ; Harki, Daniel A. ; Pomerantz, William C.K. / Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. In: Journal of medicinal chemistry. 2018 ; Vol. 61, No. 20. pp. 9316-9334.

@article{1ade36d435424c278acfd423c21a50cd,

title = "Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor",

abstract = "As regulators of transcription, epigenetic proteins that interpret post-translational modifications to N-terminal histone tails are essential for maintaining cellular homeostasis. When dysregulated, {"}reader{"} proteins become drivers of disease. In the case of bromodomains, which recognize N-ϵ-acetylated lysine, selective inhibition of individual bromodomain-and-extra-terminal (BET)-family bromodomains has proven challenging. We describe the >55-fold N-terminal-BET bromodomain selectivity of 1,4,5-trisubstituted-imidazole dual kinase-bromodomain inhibitors. Selectivity for the BRD4 N-terminal bromodomain (BRD4(1)) over its second bromodomain (BRD4(2)) arises from the displacement of ordered waters and the conformational flexibility of lysine-141 in BRD4(1). Cellular efficacy was demonstrated via reduction of c-Myc expression, inhibition of NF-κB signaling, and suppression of IL-8 production through potential synergistic inhibition of BRD4(1) and p38α. These dual inhibitors provide a new scaffold for domain-selective inhibition of BRD4, the aberrant function of which plays a key role in cancer and inflammatory signaling.",

author = "Anand Divakaran and Talluri, {Siva K.} and Ayoub, {Alex M.} and Mishra, {Neeraj K.} and Huarui Cui and Widen, {John C.} and Norbert Berndt and Zhu, {Jin Yi} and Carlson, {Angela S.} and Topczewski, {Joseph J.} and Schonbrunn, {Ernst K.} and Harki, {Daniel A.} and Pomerantz, {William C.K.}",

note = "Funding Information: This work was supported by the NSF (Grant CHE-1352019, W.C.K.P.) AHA (Grant 15SDG25710427, W.C.K.P.), NIGMS (Grant R35GM124718), and the University of Minnesota Masonic Cancer Center (Pre-R01 pilot grant D.A.H. and W.C.K.P.). A.D. was supported by the NIH Chemistry-Biology Interface Training Grant at the University of Minnesota (5T32GM008700-18). Isothermal-titration calorimetry and nuclear-magnetic-resonance spectroscopy were carried out using instruments funded by NIH Shared Instrumentation Grants (S10-OD017982 and S10-OD011952, respectively). We also thank the Moffitt Chemical Biology Core for use of the protein crystallography facility (NCI Grant P30-CA076292). BI-BODIPY was a generous gift from Wei Zhang at the University of Massachusetts, Boston. We thank Prof. Brian Smith for providing the BRD4 Bromodomain construct BRD4 (1 + 2) spanning residues 38-460.",

year = "2018",

month = oct,

day = "25",

doi = "10.1021/acs.jmedchem.8b01248",

language = "English (US)",

volume = "61",

pages = "9316--9334",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "20",

}

TY - JOUR

T1 - Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor

AU - Divakaran, Anand

AU - Talluri, Siva K.

AU - Ayoub, Alex M.

AU - Mishra, Neeraj K.

AU - Cui, Huarui

AU - Widen, John C.

AU - Berndt, Norbert

AU - Zhu, Jin Yi

AU - Carlson, Angela S.

AU - Topczewski, Joseph J.

AU - Schonbrunn, Ernst K.

AU - Harki, Daniel A.

AU - Pomerantz, William C.K.

N1 - Funding Information: This work was supported by the NSF (Grant CHE-1352019, W.C.K.P.) AHA (Grant 15SDG25710427, W.C.K.P.), NIGMS (Grant R35GM124718), and the University of Minnesota Masonic Cancer Center (Pre-R01 pilot grant D.A.H. and W.C.K.P.). A.D. was supported by the NIH Chemistry-Biology Interface Training Grant at the University of Minnesota (5T32GM008700-18). Isothermal-titration calorimetry and nuclear-magnetic-resonance spectroscopy were carried out using instruments funded by NIH Shared Instrumentation Grants (S10-OD017982 and S10-OD011952, respectively). We also thank the Moffitt Chemical Biology Core for use of the protein crystallography facility (NCI Grant P30-CA076292). BI-BODIPY was a generous gift from Wei Zhang at the University of Massachusetts, Boston. We thank Prof. Brian Smith for providing the BRD4 Bromodomain construct BRD4 (1 + 2) spanning residues 38-460.

PY - 2018/10/25

Y1 - 2018/10/25

N2 - As regulators of transcription, epigenetic proteins that interpret post-translational modifications to N-terminal histone tails are essential for maintaining cellular homeostasis. When dysregulated, "reader" proteins become drivers of disease. In the case of bromodomains, which recognize N-ϵ-acetylated lysine, selective inhibition of individual bromodomain-and-extra-terminal (BET)-family bromodomains has proven challenging. We describe the >55-fold N-terminal-BET bromodomain selectivity of 1,4,5-trisubstituted-imidazole dual kinase-bromodomain inhibitors. Selectivity for the BRD4 N-terminal bromodomain (BRD4(1)) over its second bromodomain (BRD4(2)) arises from the displacement of ordered waters and the conformational flexibility of lysine-141 in BRD4(1). Cellular efficacy was demonstrated via reduction of c-Myc expression, inhibition of NF-κB signaling, and suppression of IL-8 production through potential synergistic inhibition of BRD4(1) and p38α. These dual inhibitors provide a new scaffold for domain-selective inhibition of BRD4, the aberrant function of which plays a key role in cancer and inflammatory signaling.

AB - As regulators of transcription, epigenetic proteins that interpret post-translational modifications to N-terminal histone tails are essential for maintaining cellular homeostasis. When dysregulated, "reader" proteins become drivers of disease. In the case of bromodomains, which recognize N-ϵ-acetylated lysine, selective inhibition of individual bromodomain-and-extra-terminal (BET)-family bromodomains has proven challenging. We describe the >55-fold N-terminal-BET bromodomain selectivity of 1,4,5-trisubstituted-imidazole dual kinase-bromodomain inhibitors. Selectivity for the BRD4 N-terminal bromodomain (BRD4(1)) over its second bromodomain (BRD4(2)) arises from the displacement of ordered waters and the conformational flexibility of lysine-141 in BRD4(1). Cellular efficacy was demonstrated via reduction of c-Myc expression, inhibition of NF-κB signaling, and suppression of IL-8 production through potential synergistic inhibition of BRD4(1) and p38α. These dual inhibitors provide a new scaffold for domain-selective inhibition of BRD4, the aberrant function of which plays a key role in cancer and inflammatory signaling.

UR - http://www.scopus.com/inward/record.url?scp=85055120156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055120156&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b01248

DO - 10.1021/acs.jmedchem.8b01248

M3 - Article

C2 - 30253095

AN - SCOPUS:85055120156

VL - 61

SP - 9316

EP - 9334

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 20

ER -